AEMD 0.41 Aethlon Medical, Inc.
| Range: | 0.24-2.35 | Vol Avg: | 1729385 | Last Div: | 0 | Changes: | 0 |
| Beta: | 1.75 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 04 1999 | Empoloyees: | 14 | ||
| CUSIP: | 00808Y307 | CIK: | 0000882291 | ISIN: | US00808Y4061 | Country: | US |
| CEO: | Mr. James B. Frakes M.B.A. | Website: | https://www.aethlonmedical.com | ||||
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow